EA201390814A1 - Перорально распадающаяся таблетка - Google Patents

Перорально распадающаяся таблетка

Info

Publication number
EA201390814A1
EA201390814A1 EA201390814A EA201390814A EA201390814A1 EA 201390814 A1 EA201390814 A1 EA 201390814A1 EA 201390814 A EA201390814 A EA 201390814A EA 201390814 A EA201390814 A EA 201390814A EA 201390814 A1 EA201390814 A1 EA 201390814A1
Authority
EA
Eurasian Patent Office
Prior art keywords
orally
active ingredients
proton pump
pump inhibitor
falling tablet
Prior art date
Application number
EA201390814A
Other languages
English (en)
Inventor
Ясуси Мима
Тецуя Кавано
Юмико Исии
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201390814(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA201390814A1 publication Critical patent/EA201390814A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Представленное изобретение относится к многослойной перорально распадающейся таблетке, имеющей (1) слой, заключающий в себе кишечнорастворимые мелкие гранулы, содержащие ингибитор протонной помпы, и (2) слой, заключающий в себе ацетилсалициловую кислоту, которая демонстрирует высокую стабильность активных ингредиентов (ингибитор протонной помпы, аспирин) и проявляет фармакологическое действие активных ингредиентов стабильно и быстро после применения.
EA201390814A 2010-12-03 2011-12-02 Перорально распадающаяся таблетка EA201390814A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010270276 2010-12-03
PCT/JP2011/077978 WO2012074110A1 (ja) 2010-12-03 2011-12-02 口腔内崩壊錠

Publications (1)

Publication Number Publication Date
EA201390814A1 true EA201390814A1 (ru) 2013-11-29

Family

ID=46172031

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390814A EA201390814A1 (ru) 2010-12-03 2011-12-02 Перорально распадающаяся таблетка

Country Status (21)

Country Link
US (1) US20130243859A1 (ru)
EP (1) EP2647381A4 (ru)
JP (1) JP6037840B2 (ru)
KR (1) KR101908748B1 (ru)
CN (1) CN103338774A (ru)
AU (1) AU2011337549A1 (ru)
BR (1) BR112013013571A2 (ru)
CA (1) CA2819460C (ru)
CL (1) CL2013001566A1 (ru)
CO (1) CO6721054A2 (ru)
CR (1) CR20130287A (ru)
DO (1) DOP2013000122A (ru)
EA (1) EA201390814A1 (ru)
EC (1) ECSP13012717A (ru)
MX (1) MX2013006247A (ru)
MY (1) MY180677A (ru)
PE (1) PE20140005A1 (ru)
SG (1) SG190717A1 (ru)
TN (1) TN2013000229A1 (ru)
WO (1) WO2012074110A1 (ru)
ZA (1) ZA201304366B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY186477A (en) 2011-11-30 2021-07-22 Takeda Pharmaceuticals Co Dry coated tablet
JP6289367B2 (ja) 2012-06-05 2018-03-07 武田薬品工業株式会社 有核錠
TW201532635A (zh) * 2013-05-21 2015-09-01 Takeda Pharmaceutical 口腔內崩解錠
JP2015020964A (ja) * 2013-07-17 2015-02-02 日本曹達株式会社 ヒドロキシプロピルセルロース
BR112017009521A2 (pt) 2014-11-11 2017-12-19 Shionogi & Co comprimido de múltiplas camadas que contém um fármaco instável à luz
WO2016102661A1 (en) * 2014-12-23 2016-06-30 Krka, D.D., Novo Mesto Pharmaceutical tablet composition
EP3437639A1 (en) 2015-03-19 2019-02-06 Daiichi Sankyo Company, Limited Solid preparation containing colorant
US10561628B2 (en) * 2015-03-19 2020-02-18 Daiichi Sankyo Company, Limited Solid preparation including antioxidant
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP7050484B2 (ja) * 2017-12-26 2022-04-08 ライオン株式会社 積層錠、医薬製剤及び積層錠の製造方法
KR20220065997A (ko) * 2020-11-13 2022-05-23 (주)휴온스 라베프라졸 및 제산제를 포함하는 약제학적 복합제제 및 이의 제조방법
CN113230221B (zh) * 2021-04-06 2022-11-04 北京诚济制药股份有限公司 一种铝镁匹林片(ⅱ)
KR20230149188A (ko) 2022-04-19 2023-10-26 한미약품 주식회사 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물
KR20240043707A (ko) 2022-09-27 2024-04-03 한미약품 주식회사 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPH072761B2 (ja) 1985-03-20 1995-01-18 不二パウダル株式会社 微結晶セルロ−ス球形顆粒及びその製造法
JP2820829B2 (ja) 1991-03-07 1998-11-05 武田薬品工業株式会社 有核散剤およびその製造方法
US5798120A (en) * 1993-10-12 1998-08-25 Tokyo Tanabe Company Limited Enteric granule-containing tablets
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
JP3828648B2 (ja) 1996-11-14 2006-10-04 武田薬品工業株式会社 ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
DE60124692T2 (de) 2000-04-28 2007-09-13 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von optisch-aktiven sulfoxid-derivaten
ES2521690T3 (es) 2000-05-15 2014-11-13 Takeda Pharmaceutical Company Limited Procedimiento para producir un cristal de (R)-2-[[[3-metil-4-(2,2,2-trifluoroetoxi)-2-piridil]metil]sulfinil]-bencimidazol
JP2002029964A (ja) * 2000-07-11 2002-01-29 Lion Corp 固形医薬組成物
JP2002154966A (ja) * 2000-11-22 2002-05-28 Taisho Pharmaceut Co Ltd アセチルサリチル酸アルミニウム含有組成物
PT1337525E (pt) 2000-12-01 2011-09-01 Takeda Pharmaceutical Processo para a cristalização de (r)- ou (s)-lansoprazole
ATE474559T1 (de) 2001-06-01 2010-08-15 Pozen Inc Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid
US8206741B2 (en) * 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
JP5138856B2 (ja) * 2001-06-20 2013-02-06 武田薬品工業株式会社 錠剤の製造方法
KR20040018463A (ko) * 2001-07-16 2004-03-03 아스트라제네카 아베 양성자 펌프 억제제 및 제산제를 함유하는 제약 제제
US6930099B2 (en) * 2001-09-07 2005-08-16 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
CA2554271A1 (en) 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
CA2566655C (en) * 2004-05-25 2013-04-16 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
CN101316596A (zh) * 2005-11-30 2008-12-03 阿斯利康(瑞典)有限公司 含有质子泵抑制剂和乙酰水杨酸作为活性成份的口服药物剂型
WO2008002529A2 (en) * 2006-06-26 2008-01-03 Capricorn Pharma, Inc. Orally disintegrating layered compositions
JP2009263305A (ja) * 2008-04-28 2009-11-12 Lion Corp 多層錠剤およびその製造方法
JPWO2009151116A1 (ja) * 2008-06-13 2011-11-17 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬

Also Published As

Publication number Publication date
US20130243859A1 (en) 2013-09-19
CL2013001566A1 (es) 2014-05-02
CA2819460C (en) 2017-08-01
KR101908748B1 (ko) 2018-10-16
MX2013006247A (es) 2014-01-31
JPWO2012074110A1 (ja) 2014-05-19
KR20130124344A (ko) 2013-11-13
ECSP13012717A (es) 2013-12-31
DOP2013000122A (es) 2013-12-15
TN2013000229A1 (en) 2014-11-10
BR112013013571A2 (pt) 2016-10-11
EP2647381A4 (en) 2015-12-23
SG190717A1 (en) 2013-07-31
AU2011337549A1 (en) 2013-07-04
WO2012074110A1 (ja) 2012-06-07
CR20130287A (es) 2013-10-07
EP2647381A1 (en) 2013-10-09
MY180677A (en) 2020-12-05
CO6721054A2 (es) 2013-07-31
CN103338774A (zh) 2013-10-02
JP6037840B2 (ja) 2016-12-07
CA2819460A1 (en) 2012-06-07
ZA201304366B (en) 2014-02-26
PE20140005A1 (es) 2014-01-23

Similar Documents

Publication Publication Date Title
EA201390814A1 (ru) Перорально распадающаяся таблетка
EA201390793A1 (ru) Способ получения фармацевтической композиции, содержащей ипн
AR089032A1 (es) Comprimido recubierto seco
PE20180931A1 (es) Metodo de cristalizacion y biodisponibilidad
AR057181A1 (es) Nueva forma de dosificacion de combinacion
CL2016000143A1 (es) Comprimido farmacéutico que comprende ácido acetilsalicílico y clopidogrel
EA201200038A1 (ru) Новые соли ацетилсалициловой кислоты
BR112012028090A2 (pt) comprimidos de meloxicam de baixa concentração
MY184077A (en) Orally disintegrable tablet
EA201291136A1 (ru) Энтеросолюбильная таблетка
EA201171399A1 (ru) Способ и композиция для улучшения всасывания лекарственных средств
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
NZ628079A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
TR201010683A1 (tr) Vildagliptin formülasyonları.
EA201500245A1 (ru) Твердый фармацевтический препарат, который содержит левотироксин
BR112018001859A2 (pt) comprimido, e, método para produzir um comprimido.
JP2018118936A5 (ru)
RU2015106762A (ru) Фармацевтическая композиция для лечения недержания мочи и способ ее применения
GEP201706743B (en) Oral formulation for the treatment of cardiovascular diseases
DK2293791T3 (da) Farmaceutiske præparater med entacapon co-mikroniseret med sukkeralkoholer
ECSP11011212A (es) Nueva asociación de ingredientes activos que contienen un fármaco antiinflamatorio, no esteroideo y un derivado de colchicósido
UA59388U (ru) Комбинированный лекарственный препарат анальгетического, противовоспалительного и жаропонижающего действия
TH153153A (th) ยาเม็ดเคลือบแห้ง
CR20150411A (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol
TH134258B (th) ยาเม็ดที่แตกตัวในปาก